Medical device company ResMed (NYSE: RMD) will be announcing earnings results this Thursday afternoon. Here’s what to look for.
ResMed beat analysts’ revenue expectations last quarter, reporting revenues of $1.42 billion, up 11% year on year. It was a strong quarter for the company, with a decent beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
Is ResMed a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting ResMed’s revenue to grow 10% year on year, improving from the 7.9% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ResMed has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at ResMed’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 23%, beating analysts’ expectations by 5.8%, and Neogen reported a revenue decline of 4.4%, topping estimates by 3.4%. Intuitive Surgical traded up 7.2% following the results while Neogen was down 8.9%.
Read our full analysis of Intuitive Surgical’s results here and Neogen’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 10.8% on average over the last month. ResMed is down 1% during the same time and is heading into earnings with an average analyst price target of $289.93 (compared to the current share price of $217.83).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
